Stocks · News reference
As of Aug. 27, 2026, three health care stocks are overbought and could be giving a real warning to momentum investors, according to the RSI indicator.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Revolution Medicines, Inc. (NASDAQ:RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that
Revolution Medicines announced publication of Phase 1/2 clinical trial data for RASONQUE (daraxonrasib) in previously treated RAS mutant non-small cell lung cancer in the New England Journal of Medicine. The trial showed a 42% objective response rate and 16.0 months median overall survival in a docetaxel-naïve subgroup, with a manageable safety profile. Results support the ongoing Phase 3 RASolve 301 trial.
Bernie Sanders blasts Big Pharma over $400,000 cancer drugs, warning soaring treatment costs can push patients into financial ruin.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. BMO Capital cut the price
Veeva Systems raised its fiscal 2027 revenue guidance to $3.682-$3.687B (implying ~15% growth), driven by strong Vault CRM adoption with commitments from 12 of top 20 biopharma firms and 180+ live customers. The company's Falcon AI product has five early adopters, though execution remains a key near-term priority. While profitability is maintained with a 44% operating margin, newer initiatives like CRM migrations and AI monetization still require sustained execution.
Recent earnings in life sciences technology reveal that the market is rewarding companies with proprietary data and systems of record over those selling software or AI models alone. Veeva Systems beat expectations with strong AI product adoption, while Certara missed on modest software growth and Recursion Pharmaceuticals fell short on revenue expectations. MindWalk Holdings, which owns curated biological data infrastructure, is positioned to benefit from this trend with its HYFT Technology and newly launched ReefIQ platform, though it remains unprofitable with modest recurring revenue.